VentriPoint Diagnostics (VPT.V) Action Cours

VentriPoint Diagnostics Ltd. is a medical device company, which engages in the development and commercialization of diagnostic tools that monitor patients with heart disease. The company is headquartered in Toronto, Ontario. The company went IPO on 2005-11-09. The firm is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. The company is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The Company’s Ventripoint Medical System (VMS+) is a diagnostic aid that was developed to provide a point-of-care solution to better communicate the heart’s structure and function without the need for magnetic resonance imaging (MRI). VMS+ enhances ultrasound, providing three-dimensional (3D) technology that allows for visualization of all four chambers of the heart. The system’s proprietary Knowledge Based Reconstruction (KBR) technology creates 3D models of the heart and calculates volumes and ejection fractions equivalent to the gold-standard Magnetic resonance imaging (MRI).